Doutor Nichires Holdings Co., Ltd. (JP:3087)
:3087
Top Page
Doutor Nichires Holdings Co., Ltd.
(3087)
Select Model
Select Model
Rating:73Outperform
Price Target:
¥3,207.00
▲(23.44% Upside)
Action:ReiteratedDate:03/24/26
The score is driven primarily by strong fundamentals, led by an exceptionally low-debt balance sheet and improving profitability. Offsetting this is uneven cash-flow consistency and only moderate technical strength (near-term softness despite a longer-term uptrend). Valuation is supportive with a mid-range P/E and a modest dividend yield.
Positive Factors
Very low leverage
A very low debt-to-equity ratio (~2% in 2025) provides durable financial flexibility and low solvency risk. This balance-sheet strength supports investment in franchise growth, store refreshes or opportunistic M&A without stressing liquidity, improving resilience through cycles.
Negative Factors
Uneven cash-flow consistency
Cash-flow quality has been inconsistent across cycles: operating cash flow was negative in 2021, free cash flow near break-even in 2023, and 2025 FCF trails net income. This volatility risks that accounting profits may not reliably convert to usable cash for reinvestment or payouts over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
A very low debt-to-equity ratio (~2% in 2025) provides durable financial flexibility and low solvency risk. This balance-sheet strength supports investment in franchise growth, store refreshes or opportunistic M&A without stressing liquidity, improving resilience through cycles.
Read all positive factors
Doutor Nichires Holdings Co., Ltd. (3087) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥132.56B
Dividend Yield2.09%
Average Volume (3M)126.76K
Price to Earnings (P/E)14.7
Beta (1Y)0.35
Revenue Growth5.78%
EPS Growth10.26%
CountryJP
Employees2,765
SectorConsumer Cyclical
Sector Strength84
IndustryRestaurants
Share Statistics
EPS (TTM)43.35
Shares Outstanding45,609,760
10 Day Avg. Volume95,670
30 Day Avg. Volume126,763
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)1.01
Price to Sales (P/S)0.70
P/FCF Ratio16.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)180.86
Revenue Forecast (FY)¥164.00B
Doutor Nichires Holdings Co., Ltd. Business Overview & Revenue Model
Company Description
DOUTOR NICHIRES Holdings Co., Ltd. manages restaurants and cafes in Japan. It manufactures and sells bread and pastry products; roasts and sells coffee; and imports, exports, purchases, and sells food products. The company also engages in the manu...
How the Company Makes Money
null...
Doutor Nichires Holdings Co., Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
67
Positive
| Breakdown | TTM | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 | Feb 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 151.23B | 148.82B | 140.63B | 126.86B | 109.36B | 96.14B |
| Gross Profit | 90.45B | 89.62B | 84.19B | 74.77B | 64.31B | 55.77B |
| EBITDA | 14.03B | 14.20B | 11.58B | 6.88B | 2.40B | 197.00M |
| Net Income | 6.58B | 6.88B | 5.49B | 3.43B | 1.22B | -10.98B |
Balance Sheet | ||||||
| Total Assets | 133.54B | 134.23B | 127.79B | 121.04B | 118.23B | 115.65B |
| Cash, Cash Equivalents and Short-Term Investments | 33.34B | 38.99B | 35.80B | 32.22B | 34.55B | 26.31B |
| Total Debt | 2.04B | 2.11B | 2.77B | 2.03B | 1.54B | 1.97B |
| Total Liabilities | 32.33B | 29.88B | 28.31B | 24.74B | 24.11B | 21.65B |
| Stockholders Equity | 100.86B | 104.00B | 99.16B | 96.02B | 93.86B | 93.78B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 6.49B | 7.33B | 142.00M | 10.43B | -7.93B |
| Operating Cash Flow | 0.00 | 12.35B | 11.79B | 5.17B | 14.64B | -2.88B |
| Investing Cash Flow | 0.00 | -6.23B | -4.90B | -5.59B | -4.93B | -5.95B |
| Financing Cash Flow | 0.00 | -2.93B | -3.37B | -1.98B | -1.50B | -2.15B |
Doutor Nichires Holdings Co., Ltd. Technical Analysis
Positive
2598.00
Price Trends
2922.44
Positive
2740.25
Positive
2638.02
Positive
Market Momentum
37.92
Negative
61.63
Neutral
84.97
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3087, the sentiment is Positive. The current price of 2598 is below the 20-day moving average (MA) of 2963.05, below the 50-day MA of 2922.44, and below the 200-day MA of 2638.02, indicating a bullish trend. The MACD of 37.92 indicates Negative momentum. The RSI at 61.63 is Neutral, neither overbought nor oversold. The STOCH value of 84.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3087.
Doutor Nichires Holdings Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥132.56B | 14.74 | ― | 2.09% | 5.78% | 10.26% | |
70 Outperform | ¥131.97B | 20.09 | ― | 0.70% | 5.15% | 47.13% | |
68 Neutral | ¥141.52B | 20.64 | ― | 1.88% | 16.70% | -0.37% | |
66 Neutral | ¥143.67B | 22.93 | 9.66% | 1.17% | 8.16% | -6.01% | |
65 Neutral | ¥273.30B | 33.85 | 9.66% | 0.55% | 14.33% | 36.83% | |
63 Neutral | ¥750.98B | 45.71 | 9.53% | 0.55% | 15.58% | 60.90% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
* Consumer Cyclical Sector Average
JP:3087
Doutor Nichires Holdings Co., Ltd.
2,998.00
667.41
28.64%
JP:8179
Royal Holdings Co
1,472.00
180.39
13.97%
JP:3197
Skylark Holdings Co
3,231.00
279.52
9.47%
JP:7581
Saizeriya Co
5,600.00
1,671.28
42.54%
JP:3543
KOMEDA Holdings Co., Ltd.
3,060.00
220.00
7.75%
JP:8153
MOS FOOD SERVICES, INC.
4,280.00
536.80
14.34%
Doutor Nichires Holdings Co., Ltd. Corporate Events
Doutor-Nichires Lifts Dividend Forecast as Earnings Recover Despite Cost Pressures
Jan 14, 2026
Doutor-Nichires Holdings has revised upward its dividend forecast for the fiscal year ending February 2026, citing steady sales growth and a recovery in performance in the second half of the year despite pressures from higher raw material costs an...
DOUTOR·NICHIRES Posts Higher Sales but Flat Profits, Lifts Dividend and Keeps Outlook
Jan 14, 2026
DOUTOR·NICHIRES Holdings reported consolidated net sales of ¥119.7 billion for the nine months ended November 30, 2025, up 6.5% year on year, while operating profit was almost flat at ¥8.0 billion and profit attributable to owners o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.